Detail akcie Evotec OAI online

Business Summary: Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Evotec SE revenues increased 2% to EUR797M. Net loss applicable to common stockholders increased from EUR83.9M to EUR196.1M. Revenues reflect Just Evotec Biologics segment increase of 71% to EUR185.6M, Switzerland segment increase of 68% to EUR109M, United Kingdom segment increase of 7% to EUR92.5M. Higher net loss reflects Shared R&D segment loss increase from EUR8.1M to EUR126.2M.